MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Kent Hawryluk, President and CEO, will deliver a presentation on January 14th, 2025, at 2:15 p.m. Pacific Time.

The company will engage in one-on-one investor meetings during the conference. A live webcast will be available through the investors section of MBX Biosciences' website, with replay access provided approximately two hours after the event and remaining accessible for about 30 days.

CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14^th, 2025, at 2:15 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference.

Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 30 days.

About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.

Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569

Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com

FAQ

When is MBX Biosciences presenting at the 2025 J.P. Morgan Healthcare Conference?

MBX Biosciences will present on Tuesday, January 14th, 2025, at 2:15 p.m. Pacific Time.

How can investors access MBX Biosciences' J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events.

How long will the MBX Biosciences presentation replay be available?

The webcast replay will be available approximately two hours after the event and will be archived on the company's website for approximately 30 days.

What type of therapies does MBX Biosciences develop?

MBX Biosciences develops novel precision peptide therapies for the treatment of endocrine and metabolic disorders.

Will MBX Biosciences conduct investor meetings at the J.P. Morgan Healthcare Conference?

Yes, MBX Biosciences will participate in one-on-one investor meetings during the conference.